Psoriasis’ pathogenesis remains unknown, and therefore effective treatment is yet to be developed.

Kynurenine pathway is one of the ways the amino acid tryptophan is metabolised.

In comorbidities typical for psoriasis such as chronic kidney disease, depression and atherosclerosis alterations in the activation of the kynurenine pathway were observed, which were mainly characterised by higher activity compared to that in healthy individuals.

Given the unknown pathogenesis of the disease, this finding seems the be a potential new field of study and a possible link between psoriasis and its comorbidities that could also lead to novel effective treatment for this chronic condition.